SOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good. We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer and rare inherited disorders. The AI fueling our platform learns from the complex genomic and multimodal data provided by our community of users to create a collective intelligence over time. By using the power of data and AI, we are expanding access to data-driven medicine and enabling the patients of today to help the patients of tomorrow. Our science is driven by unrelenting passion for our mission to transform patient care by expanding access to data-driven medicine globally. We wouldn’t be able to achieve all that we have – and all that we will – without our people, who are driven by our shared purpose to ensure that every patient worldwide has equitable access to precision medicine. Our virtues are our behaviors we exhibit every day, and our mantra “We Care” is our driving force.
解鎖市場時間軸與訊號動態
過去 90 日內有 2,182 個訊號。
此公司進入各市場的次序 — 由最舊至最新
Como o Hospital Mário Penna incorporou NGS à rotina para diagnóstico de neoplasias hematológicas?Implementar uma nova tecnologia em laboratório clínico vai muito além da parte técnica — envolve confiança, adaptação e aprendizado contínuo.Neste webinar, a equipe do Hospital Mário Penna abre as portas do seu laboratório para contar como incorporou duas aplicações de NGS à rotina para investigação de neoplasias mieloides e linfoídes, desde a avaliação do desempenho analítico até os primeiros casos ...
A experiência do Hospital Mário Penna na implementação de soluções para investigação de doenças onco-hematológicas
註冊以查看完整訊號動態
SOPHiA GENETICS 的國際擴張與競爭對手的比較
SOPHiA GENETICS你長條顯示所比較各公司之間的相對規模。
5 項指標| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 SOPHiA GENETICS你 | 11 | 0 | -54% | 2.2k | 21 |
急速擴張 — 過去 90 日內開放了 46 個職位，較上一期上升 183%。 以 Sales 為主，集中於 瑞士。
Boston, MA · 前日
Senior Software Engineer
Singapore · 5日前
Director, Subject Matter Expert - APAC
Colombia · 上星期
Associate Director / Sr Manager, BioPharma Business Development (West / Central)
整個技術架構共偵測到 50 項技術。
於 226 個市場進行 32 個活躍廣告活動。
已結束
已結束
已結束過去 90 日內有 3 則提及。
SOPHiA GENETICS SA發布了與2026年第二季度業績電話會議相關的幻燈片,Seeking Alpha提供文字記錄報導。
SOPHiA Genetics公佈2026年第二季業績,收入2,330萬美元,按年增長27.2%,超出預期。GAAP每股虧損0.30美元,遜於預期0.08美元。毛利率降至64.6%(報告基準)和72.1%(調整基準)。
SOPHiA GENETICS宣布與阿斯利康展開多年合作,開發和部署兩項精準腫瘤治療的伴隨診斷,在全球推進分散式臨床試驗檢測。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 SOPHiA GENETICS 業務、市場及增長訊號的快速解答。
